Login / Signup

Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2-Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial.

Akihiro OhbaChigusa MorizaneYasuyuki KawamotoYoshito KomatsuMakoto UenoSatoshi KobayashiMasafumi IkedaMitsuhito SasakiJunji FuruseNaohiro OkanoNobuyoshi HiraokaHiroshi YoshidaAya KuchibaRyo SadachiKenichi NakamuraNaoko MatsuiYoshiaki NakamuraWataru OkamotoTakayuki YoshinoTakuji Okusaka
Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
T-DXd showed promising activity in patients with HER2-positive BTC and a signal of efficacy in patients with HER2-low BTC. Although the safety profile was generally manageable, ILD requires careful monitoring and early intervention.
Keyphrases